Transplant expert Dr. Teuteberg joins CareDx as chief medical officer

BRISBANE, Calif. - CareDx, Inc. (NASDAQ:CDNA), a profitable healthcare company with annual revenue of $341 million and strong gross margins of 67%, has appointed Dr. Jeffrey John Teuteberg as Chief Medical Officer, effective October 1, 2025, according to a company press release. According to InvestingPro analysis, the company maintains a healthy balance sheet with more cash than debt.

Dr. Teuteberg, who has served as Section Chief of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support at Stanford University since 2017, brings over 20 years of clinical transplantation experience to the role. He is board certified in Heart Failure/Cardiac Transplantation and Cardiovascular Medicine.

In his new position, Dr. Teuteberg will lead CareDx’s global Medical Affairs activities, including oversight of Medical Directors, Medical Science Liaisons, and clinical research operations.

Prior to joining CareDx, Dr. Teuteberg held leadership positions at Stanford University and the University of Pittsburgh Medical Center. He has also served as President of the International Society for Heart and Lung Transplantation (ISHLT) and has been active in the American Society of Transplantation (AST).

Dr. Teuteberg was the principal investigator for the Surveillance HeartCare Outcomes Registry (SHORE) study, which focused on noninvasive rejection surveillance in heart transplantation.

"I am honored to join CareDx at such a pivotal time for the field of transplantation," Dr. Teuteberg said in the statement.

CareDx, based in Brisbane, California, focuses on developing precision medicine solutions for transplant patients and caregivers. The company’s stock currently trades at $14.97, with InvestingPro analysis indicating the shares are undervalued based on their Fair Value model. Healthcare investors can access detailed analysis of CareDx and 1,400+ other stocks through InvestingPro’s comprehensive Research Reports, which transform complex financial data into actionable insights.

In other recent news, CareDx, Inc. has announced several key developments. The company revealed new innovations in transplant diagnostics and received European regulatory certifications for its HLA typing products at the ASHI 2025 Annual Meeting. These include the launch of AlloSeq Tx11, an enhanced HLA typing solution, and SCORE 7 Software for improved analysis. In leadership news, CareDx appointed Suresh Gunasekaran, CEO of UCSF Health, to its Board of Directors. On the analyst front, BTIG reiterated its Buy rating for CareDx, maintaining a $22.00 price target and noting potential upside beyond an anticipated CMS decision. Meanwhile, William Blair initiated coverage of CareDx with a Market Perform rating, highlighting the company’s potential for improvement amidst recent challenges. These challenges include reimbursement difficulties, patent litigation, and executive leadership changes. Investors are keenly watching these developments for potential impacts on CareDx’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.